Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A Review of COVID-19 (coronavirus disease-2019) diagnosis, treatments and prevention. Eurasian J Med Oncol. 2019. https://doi.org/10.14744/ejmo.2020.90853.
Article
Google Scholar
Barati F, Pouresmaieli M, Ekrami E, Asghari S, Ziarani FR, Mamoudifard M. Potential drugs and remedies for the treatment of COVID-19: a critical review. Biol Proced Online. 2020;22(1):1–17.
Google Scholar
Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol Aust. 2020;41(1):45–50.
Google Scholar
De Vito A, Fiore V, Princic E, Geremia N, Panu Napodano CM, Muredda AA, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS ONE. 2021;16(3): e0248009.
PubMed
PubMed Central
Google Scholar
Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252–8.
PubMed
PubMed Central
Google Scholar
Geremia N, De Vito A, Gunnella S, Fiore V, Princic E, Napodano CP, et al. A case of vasculitis-like skin eruption associated with COVID-19. Infect Dis Clin Pract. 2020;28(6):e30–1.
Google Scholar
Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50(SI-1):620–32.
CAS
PubMed
PubMed Central
Google Scholar
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.052.
Article
PubMed
PubMed Central
Google Scholar
Khodadoost M, Niknam Z, Farahani M, Razzaghi M, Norouzinia M. Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine. Gastroenterol Hepatol Bed Bench. 2020;13(4):374.
PubMed
PubMed Central
Google Scholar
Sadrabadi AE, Bereimipour A, Jalili A, Gholipurmalekabadi M, Farhadihosseinabadi B, Seifalian AM. The risk of pancreatic adenocarcinoma following SARS-CoV family infection. Sci Rep. 2021;11(1):1–13.
Google Scholar
Farahani M, Niknam Z, Amirabad LM, Amiri-Dashatan N, Koushki M, Nemati M, et al. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother. 2021. https://doi.org/10.1016/j.biopha.2021.112420.
Article
PubMed
PubMed Central
Google Scholar
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020. https://doi.org/10.1038/s41418-020-0530-3.
Article
PubMed
PubMed Central
Google Scholar
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I-G, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2020. https://doi.org/10.1007/s10238-020-00671-y.
Article
PubMed
PubMed Central
Google Scholar
Senanayake SL. Drug repurposing strategies for COVID. Future Drug Discov. 2020. https://doi.org/10.4155/fdd-2020-0010.
Article
PubMed Central
Google Scholar
Molavi Z, Razi S, Mirmotalebisohi SA, Adibi A, Sameni M, Karami F, et al. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomed Pharmacother. 2021. https://doi.org/10.1016/j.biopha.2021.111544.
Article
PubMed
PubMed Central
Google Scholar
Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–6.
CAS
PubMed
PubMed Central
Google Scholar
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–36.
CAS
PubMed
Google Scholar
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31022-9.
Article
PubMed
PubMed Central
Google Scholar
Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11(6): e048416.
PubMed
Google Scholar
Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, et al. Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 2021;174(5):663–72.
PubMed
Google Scholar
Al-Abdouh A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu OE, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials. 2021. https://doi.org/10.1016/j.cct.2021.106272.
Article
PubMed
PubMed Central
Google Scholar
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
CAS
PubMed
Google Scholar
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies. Int J Mol Med. 2020. https://doi.org/10.3892/ijmm.2020.4608.
Article
PubMed
PubMed Central
Google Scholar
Dehelean CA, Lazureanu V, Coricovac D, Mioc M, Oancea R, Marcovici I, et al. SARS-CoV-2: repurposed drugs and novel therapeutic approaches—insights into chemical structure—biological activity and toxicological screening. J Clin Med. 2020;9(7):2084.
CAS
PubMed Central
Google Scholar
Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020. https://doi.org/10.1007/s10067-020-05190-5.
Article
PubMed
PubMed Central
Google Scholar
Chen C-x, Wang J-j, Li H, Yuan L-t, Gale RP, Liang Y. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01266-6.
Article
PubMed
PubMed Central
Google Scholar
Magro G. COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res. 2020. https://doi.org/10.1016/j.virusres.2020.198070.
Article
PubMed
PubMed Central
Google Scholar
Ma S, Xu C, Liu S, Sun X, Li R, Mao M, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Signal Transduct Target Ther. 2021;6(1):1–7.
Google Scholar
Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–41.
CAS
PubMed
Google Scholar
Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):1–8.
Google Scholar
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020. https://doi.org/10.1007/s00011-020-01401-6.
Article
PubMed
PubMed Central
Google Scholar
REMAP-CAP, ACTIV-4a, ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89.
Google Scholar
Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, Mousavizadeh M, Baay MR, Noohi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30.
Google Scholar
Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):1–11.
Google Scholar
Wei FF, Moradkhani A, Hemmati Hezaveh H, Miraboutalebi SA, Salehi L. Evaluating the treatment with favipiravir in patients infected by COVID-19: a systematic review and meta-analysis. Int J Sci Res Dent Med Sci. 2020;2(3):87–91.
CAS
Google Scholar
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1–13.
Google Scholar
Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J. 2021. https://doi.org/10.1136/postgradmedj-2021-140287.
Article
PubMed
Google Scholar
Chan H-T, Chao C-M, Lai C-C. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis. J Infect. 2021;82(4):e34–5.
CAS
PubMed
Google Scholar
Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021. https://doi.org/10.1101/2021.06.17.21258639.
Article
PubMed
PubMed Central
Google Scholar
Zhang Z, Wang S, Tu X, Peng X, Huang Y, Wang L, et al. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol. 2020;92(11):2631–6.
CAS
PubMed
Google Scholar
Fhatonah N, Dewianti ZP, Rusdiana N. The effectiveness of remdesivir versus ruxolitinib as Covid-19 supportive management: systematic review, meta-analysis. 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020); 2021. Atlantis Press.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137-46. e3.
CAS
PubMed
PubMed Central
Google Scholar
Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2101643.
Article
PubMed
PubMed Central
Google Scholar
Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00237-X.
Article
PubMed
PubMed Central
Google Scholar
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–300.
CAS
PubMed
PubMed Central
Google Scholar
Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango D, Laniado H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS ONE. 2021;16(5): e0252057.
PubMed
PubMed Central
Google Scholar
Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020. https://doi.org/10.1183/13993003.02808-2020.
Article
PubMed
PubMed Central
Google Scholar
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):1–8.
Google Scholar
Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00160-0.
Article
PubMed
PubMed Central
Google Scholar
Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–55.
CAS
PubMed
PubMed Central
Google Scholar
Lin Y, Wu F, Xie Z, Song X, Zhu Q, Wei J, et al. Clinical study of artesunate in the treatment of coronavirus disease 2019. Zhonghua wei zhong bing ji jiu yi xue. 2020;32(4):417–20.
PubMed
Google Scholar
Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn-schmiedeberg’s Arch Pharmacol. 2021. https://doi.org/10.1007/s00210-021-02061-x.
Article
Google Scholar
Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Cruz CSD, et al. Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. medRxiv. 2020. https://doi.org/10.1101/2020.08.10.20172189.
Article
PubMed
PubMed Central
Google Scholar
Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. medRxiv. 2020. https://doi.org/10.1101/2020.08.04.20167205.
Article
PubMed
PubMed Central
Google Scholar
Kow CS, Ming LC, Hasan SS. Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Hypertens Res. 2021. https://doi.org/10.1038/s41440-021-00670-w.
Article
PubMed
PubMed Central
Google Scholar
Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19—a Pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021;37: 100981.
PubMed
PubMed Central
Google Scholar
Rocco PR, Silva PL, Cruz FF, Melo-Junior MAC, Tierno PF, Moura MA, et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021. https://doi.org/10.1183/13993003.03725-2020.
Article
PubMed
PubMed Central
Google Scholar
Abdulamir AS, Gorial FI, Saaedi SJ, Maulood MF, Hashim HA. Effectiveness and safety of niclosamaide as add-on therapy to the standard of care measures in COVID-19 management: randomized controlled clinical trial. medRxiv. 2021. https://doi.org/10.1101/2021.06.10.21258709.
Article
Google Scholar
Ansarin K, Tolouian R, Ardalan M, Taghizadieh A, Varshochi M, Teimouri S, et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a randomized clinical trial. BioImpacts. 2020;10(4):209.
CAS
PubMed
PubMed Central
Google Scholar
Mikhaylov EN, Lyubimtseva TA, Vakhrushev AD, Stepanov D, Lebedev DS, Vasilieva EY, et al. Bromhexine hydrochloride prophylaxis of COVID-19 for medical personnel: a randomized open-label study. medRxiv. 2021. https://doi.org/10.1101/2021.03.03.21252855.
Article
Google Scholar
Toma A, Darwish C, Taylor M, Harlacher J, Darwish R. The use of dornase alfa in the management of COVID-19-associated adult respiratory distress syndrome. Crit Care Res Pract. 2021. https://doi.org/10.1155/2021/8881115.
Article
PubMed
PubMed Central
Google Scholar
Weber AG, Chau AS, Egeblad M, Barnes BJ, Janowitz T. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series. Mol Med. 2020;26(1):1–7.
Google Scholar
Uusalo P, Valtonen M, Järvisalo MJ. Hemodynamic and respiratory effects of dexmedetomidine sedation in critically Ill Covid-19 patients. A retrospective cohort study. Acta Anaesthesiol Scand. 2021. https://doi.org/10.1111/aas.13970.
Article
PubMed
PubMed Central
Google Scholar
Ju T, Lee CC, Chen W-c, Lin H-T. Use of dexmedetomidine in critically ill patients receiving noninvasive ventilation: a meta-analysis of randomized controlled trials. Chest. 2020;158(4):A577.
Google Scholar
Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot A-S, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01021-4.
Article
PubMed
PubMed Central
Google Scholar
Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102554.
Article
PubMed
PubMed Central
Google Scholar
Van Erp EA, Luytjes W, Ferwerda G, Van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548.
PubMed
PubMed Central
Google Scholar
Gunn BM, Yu W-H, Karim MM, Brannan JM, Herbert AS, Wec AZ, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell Host Microbe. 2018;24(2):221-33. e5.
CAS
PubMed
PubMed Central
Google Scholar
Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39–44.
CAS
PubMed
PubMed Central
Google Scholar
Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clin Proc. 2021. https://doi.org/10.1016/j.mayocp.2021.02.008.
Article
PubMed
Google Scholar
Prasad M, Seth T, Elavarasi A. Efficacy and safety of convalescent plasma for COVID-19: a systematic review and meta-analysis. Indian J Hematol Blood Transfus. 2021. https://doi.org/10.1007/s12288-021-01417-w.
Article
PubMed
PubMed Central
Google Scholar
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020. https://doi.org/10.1101/2020.08.12.20169359.
Article
PubMed
PubMed Central
Google Scholar
Cheraghali AM, Abolghasemi H, Eshghi P. Management of COVID-19 virus infection by convalescent plasma. Iran J Allergy Asthma Immunol. 2020. https://doi.org/10.18502/ijaai.v19i(s1.r1).2847.
Article
PubMed
Google Scholar
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–8.
CAS
PubMed
Google Scholar
Jafari A, Mostafa R-T, Karami S, Yazdani M, Zali H, Jafari Z. Cancer care management during the COVID-19 pandemic. Risk Manag Healthc Policy. 2020;13:1711–21.
PubMed
PubMed Central
Google Scholar
Hussen J, Kandeel M, Hemida MG, Al-Mubarak AI. Antibody-based immunotherapeutic strategies for COVID-19. Pathogens. 2020;9(11):917.
CAS
PubMed Central
Google Scholar
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020. https://doi.org/10.1021/acscentsci.0c00272.
Article
PubMed
PubMed Central
Google Scholar
Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol. 2020. https://doi.org/10.1002/jcp.30076.
Article
PubMed
PubMed Central
Google Scholar
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):1–20.
PubMed
PubMed Central
Google Scholar
Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020. https://doi.org/10.1016/j.jaut.2020.102452.
Article
PubMed
PubMed Central
Google Scholar
de Andrade Santos I, Grosche VR, Bergamini FRG, Sabino-Silva R, Jardim ACG. Antivirals against coronaviruses: candidate drugs for SARS-coV-2 treatment? Front Microbiol. 2020;11:1818.
Google Scholar
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021. https://doi.org/10.1136/thoraxjnl-2020-215266.
Article
PubMed
Google Scholar
van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome. Front Med. 2015;2:4.
Google Scholar
Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021. https://doi.org/10.1016/S2665-9913(21)00216-2.
Article
PubMed
PubMed Central
Google Scholar
Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology. 2021. https://doi.org/10.1093/rheumatology/keab447.
Article
PubMed
Google Scholar
Avdeev SN, Trushenko NV, Tsareva NA, Yaroshetskiy AI, Merzhoeva ZM, Nuralieva GS, et al. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: a pilot study. Cytokine. 2021;146: 155627.
CAS
PubMed
PubMed Central
Google Scholar
Bonaventura A, Vecchié A, Wang TS, Lee E, Cremer PC, Carey B, et al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front Immunol. 2020;11:1625.
CAS
PubMed
PubMed Central
Google Scholar
Guan J-T, Wang W-J, Jin D, Mou X-Y, Lei S-S, Xu Z-H. A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients. Ther Adv Chronic Dis. 2021;12: 20406223211039699.
CAS
PubMed
PubMed Central
Google Scholar
Robson B. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput Biol Med. 2020. https://doi.org/10.1016/j.compbiomed.2020.103749.
Article
PubMed
PubMed Central
Google Scholar
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9.
CAS
PubMed
Google Scholar
Kumar S, Chandele A, Sharma A. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 2021;17(9): e1009885.
CAS
PubMed
PubMed Central
Google Scholar
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J. Bamlanivimab plus etesevimab in mild or moderate Covid-19. New England J Med. 2021;385(15):1382–92. https://doi.org/10.1056/NEJMoa2102685.
Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. 2021. https://www.fda.gov/media/145802/download. Accessed 17 Feb 2021.
Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021;326(1):46–55.
CAS
PubMed
Google Scholar
O'Brien MP, Neto EF, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB. Subcutaneous REGEN-COV antibody combination for Covid-19 prevention. medRxiv. 2021. https://doi.org/10.1056/NEJMoa2109682.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00542-x.
Article
PubMed
PubMed Central
Google Scholar
Sakoulas G, Geriak M, Kullar R, Greenwood KL, Habib M, Vyas A, et al. Intravenous immunoglobulin plus methylprednisolone mitigate respiratory morbidity in coronavirus disease 2019. Crit Care Explor. 2020. https://doi.org/10.1097/CCE.0000000000000280.
Article
PubMed
PubMed Central
Google Scholar
Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunol. 2020;9(10): e1198.
CAS
Google Scholar
Cheng MH, Zhang S, Porritt RA, Rivas MN, Paschold L, Willscher E, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci. 2020;117(41):25254–62.
CAS
PubMed
PubMed Central
Google Scholar
Xiang H-r, Cheng X, Li Y, Luo W-w, Zhang Q-z, Peng W-x. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): a meta-analysis. Int Immunopharmacol. 2019;2021(96): 107732.
Google Scholar
Golchin A. Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility. Stem Cell Rev Rep. 2020. https://doi.org/10.1007/s12015-020-10046-1.
Article
PubMed
PubMed Central
Google Scholar
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020. https://doi.org/10.1007/s12015-020-09973-w.
Article
PubMed
PubMed Central
Google Scholar
Golchin A, Rekabgardan M, Taheri RA, Nourani MR. Promotion of cell-based therapy: special focus on the cooperation of mesenchymal stem cell therapy and gene therapy for clinical trial studies. Cell Biol Transl Med. 2018;4:103–18.
Google Scholar
Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep. 2019;15(2):166–75.
PubMed
Google Scholar
Golchin A, Farahany TZ, Khojasteh A, Soleimanifar F, Ardeshirylajimi A. The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review. Curr Stem Cell Res Ther. 2019;14(1):22–33.
CAS
PubMed
Google Scholar
Razi S, Molavi Z, Mirmotalebisohi SA, Niknam Z, Sameni M, Niazi V, et al. Mesenchymal stem cells in the treatment of new coronavirus pandemic: a novel promising therapeutic approach. Adv Pharm Bull. 2021. https://doi.org/10.34172/apb.2022.023.
Article
Google Scholar
Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019. https://doi.org/10.1155/2019/9628536.
Article
PubMed
PubMed Central
Google Scholar
Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 2020;11(2):462.
PubMed
PubMed Central
Google Scholar
Kavianpour M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther. 2020;11(1):1–19.
Google Scholar
Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, et al. Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis. Stem Cells Dev. 2021. https://doi.org/10.1089/scd.2021.0179.
Article
PubMed
PubMed Central
Google Scholar
Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660–73.
CAS
PubMed
PubMed Central
Google Scholar
Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6(1):1–9.
Google Scholar
Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.
CAS
PubMed
PubMed Central
Google Scholar
Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):1–11.
Google Scholar
Hashemian S-MR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini S-E, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):1–12.
Google Scholar
Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14(5):664–73.
PubMed
Google Scholar
Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med. 2021;11(2): e297.
CAS
PubMed
PubMed Central
Google Scholar
Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. 2020;25: 100454.
PubMed
PubMed Central
Google Scholar
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216.
PubMed
PubMed Central
Google Scholar
Market M, Angka L, Martel AB, Bastin D, Olanubi O, Tennakoon G, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol. 2020. https://doi.org/10.3389/fimmu.2020.01512.
Article
PubMed
PubMed Central
Google Scholar
Korang SK, Juul S, Nielsen EE, Feinberg J, Siddiqui F, Ong G, et al. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). Syst Rev. 2020;9(1):1–15.
Google Scholar
Li Y-D, Chi W-Y, Su J-H, Ferrall L, Hung C-F, Wu T-C. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):1–23.
CAS
PubMed
PubMed Central
Google Scholar
Darbar S, Saha S, Agarwal S. Immunomodulatory role of vitamin C, D and E to fight against COVID-19 infection through boosting immunity: a review. Parana J Sci Educ. 2021;7(1):10–8.
Google Scholar
Corrao S, Mallaci Bocchio R, Lo Monaco M, Natoli G, Cavezzi A, Troiani E, et al. Does evidence exist to blunt inflammatory response by nutraceutical supplementation during COVID-19 pandemic? An overview of systematic reviews of vitamin D, vitamin C, Melatonin, and zinc. Nutrients. 2021;13(4):1261.
CAS
PubMed
PubMed Central
Google Scholar
Clemente-Suárez VJ, Ramos-Campo DJ, Mielgo-Ayuso J, Dalamitros AA, Nikolaidis PA, Hormeño-Holgado A, et al. Nutrition in the actual COVID-19 pandemic. A narrative review. Nutrients. 2021;13(6):1924.
PubMed
PubMed Central
Google Scholar
Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care. 2021;11(1):1–12.
Google Scholar
Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid-19: a randomized clinical trial. Nutrients. 2021;13(7):2170.
CAS
PubMed
PubMed Central
Google Scholar
Basiri A, Mansouri F, Azari A, Ranjbarvan P, Zarein F, Heidari A, et al. Stem cell therapy potency in personalizing severe COVID-19 treatment. Stem Cell Rev Rep. 2021. https://doi.org/10.1007/s12015-020-10110-w.
Article
PubMed
PubMed Central
Google Scholar